Opportunistic Infections
Seattle, WA March 5 - 8, 2011
Provided by NATAP
- CROI: GS-7977 + Ribavirin in HCV
Genotype 1 Null Responders: Results from the ELECTRON Trial - (03/7/11)
- CROI: PHARMACOKINETIC INTERACTION
BETWEEN THE HCV PROTEASE INHIBITOR BOCEPREVIR AND RITONAVIR-BOOSTED HIV-1
PROTEASE INHIBITORS ATAZANAVIR, LOPINAVIR, AND DARUNAVIR - (03/7/11)
- CROI: The Pharmacokinetic
Interactions of HCV Protease Inhibitor TMC435 with Rilpivirine, Tenofovir,
Efavirenz or Raltegravir in Healthy Volunteers - (03/7/11)
- CROI: Evaluation of NS3 Amino
Acid Variants in a Phase 1b Study of GT 1 Infection with the HCV Protease
Inhibitor, MK-5172 - (03/7/11)
- CROI: Influence of the HCV
Protease Inhibitor Boceprevir on the Pharmacokinetics of the HIV Integrase
Inhibitor Raltegravir - (03/7/11)
- CROI: Telaprevir in Combination
with Peginterferon Alfa-2a/Ribavirin in HCV/HIV Co-infected Patients: SVR12
Interim Analysis - (03/7/11)
- CROI: Boceprevir Plus
Peginterferon/Ribavirin for the Treatment of HCV/HIV Co-Infected Patients -
(03/7/11)
- CROI: HCV PI Boceprevir Lowers Levels of Three Key HIV PIs - written by Mark Mascolini - (03/7/11)
No comments:
Post a Comment